H. Shaw Warren, MD

Warren Laboratory

The Warren Laboratory researches the pathogenesis and treatment of serious bacterial infections, sepsis, and induced secondary inflammation from any cause.

About Us

The Warren Laboratory is interested in the pathogenesis and treatment of serious bacterial infections, sepsis, and induced secondary inflammation from any cause. Because sepsis is associated with overwhelming stimulation of the innate immune response with tissue damage, we are especially interested in the interactions of the bacterial cell wall with the host and the relationship of microbial clearance to induced inflammation. Our work spans from basic to translational to clinical studies. While new projects are starting all the time, our work has recently become more focused on two thrust areas.


Species Inspired Research for Innovative Treatments (SPIRIT) is an ongoing large scale project in the Warren Lab that aspires to better understand why species respond differently to inflammatory stimuli and infection. We believe that a better understanding of these species differences will permit advances in the translation of results in animal models to human settings and that exploration of the underlying mechanisms could explain heterogeneity of human responses and inspire novel approaches to treat human diseases. For more information about SPIRIT, please go to the SPIRIT section of our site.

Heme in Inflammation

A second major thrust area of the laboratory has been to study the role of heme in inflammation. We have learned that red blood cells release hemoglobin in numerous clinical settings, and that cell-free hemoglobin and liberated heme greatly amplify secondary inflammation. We are hopeful that a better understanding of these mechanisms may lead to novel approaches to block potentially damaging inflammation in tissues. For more information about the role of hemoglobin and heme in inflammation and our approaches to block it, please go to the Role of Heme in Inflammation section of our site, under the Research Projects tab.


Our Team

H. Shaw Warren, MD

H. Shaw Warren, MD is an Associate Professor of Pediatrics at Harvard Medical School. In addition, he holds appointments at Massachusetts General Hospital, Shriners Hospitals for Children – Boston, and Spaulding Rehabilitation Hospital. He is also an Associate Faculty member at the Wyss Institute. Dr. Warren graduated from Harvard College in 1973 and Harvard Medical School in 1978. He trained in Infectious Diseases at the Beth Israel Hospital and received further research training at the Dana Farber Cancer Center before doing post-graduate work for three years in the department of Experimental Immunotherapy at the Institute Pasteur, during which time he was supported by a Fulbright Fellowship and then a Mosely Fellowship from Harvard Medical School. He then returned to work at the Massachusetts General Hospital, where he has run a laboratory in the area of host response and inflammation for 25 years.

Dr. Warren is a Fellow of the Infectious Disease Society of America, and member of the American Society for Microbiology, the American Association for the Advancement of Science, Kunkel Society, Massachusetts Infectious Disease Society, and the Pediatric Infectious Disease Society. He has published over 110 articles, book chapters, reviews, letters and editorials relating to inflammation, immunity and infectious disease.

Tian Lin, MD, PhD

Tian Lin, MD, PhD is an Instructor of Pediatrics at Harvard Medical School. Dr. Lin also holds appointments at Massachusetts General Hospital and Shriners Hospitals for Children – Boston. She received her doctorate in medicine from Tongji Medical University, and she performed her medical residency and practiced Internal Medicine at the Second Affiliated Hospital of Guangdong Pharmaceutical University in China. In 2005, Dr. Lin received her PhD in Microbiology and Immunology from the University of North Carolina at Charlotte. After conducting postdoctoral training in the Department of Pathology at Tufts Medical School, Dr. Lin joined the Warren Lab in 2007.

Dr. Lin has a longstanding interest in host-pathogen interactions in infectious diseases. Her PhD research focused on the host immune response to Salmonella infection. At the Warren Lab, Dr. Lin and her colleagues discovered the synergistic inflammation induced by heme and hemoglobin with multiple microbial TLR agonists and HMGB1, and has been studying hemopexin, a serum protein, as a potential therapeutic reagent to control overactive immune responses in several clinical conditions. These studies were published in many peer reviewed journals and are now the basis for multiple translational research endeavors. Dr. Lin is the principle investigator of the Shriners Hospital for Children grant “Hemopexin suppresses inflammation in burn wounds.” In addition to conducting laboratory research, Dr. Lin teaches preclinical courses at Harvard Medical School.

Frank Riley, MS

Frank Riley, MS is the Laboratory Manager for the Warren Laboratory and a Project Manager for the SPIRIT Project. Mr. Riley received a Master of Science in Applied Medical Sciences from the University of Southern Maine in 2010. Mr. Riley studied the affects of serial passaging on adipose-derived mesenchymal stem cells and the role of mitochondrial health in intervertebral disc degeneration before joining the Warren Lab in 2012. Since joining the Warren Lab, amongst other topics, Mr. Riley has studied whether heme-related parameters can be used to predict patient outcome in various secondary infectious diseases such as ARDS, malaria and burns.

Our Research

Species Inspired Research for Innovative Treatments (SPIRIT)

The SPIRIT project is an ongoing large scale project in the Warren Lab to better understand why there is such a marked difference in sensitivity of different vertebrate species to many pro-inflammatory stimuli, including bacteria and agonists of most Toll-like receptors. SPIRIT was born out of previous work that Dr. Warren conducted while on sabbatical at the Institut Pasteur in Paris in 2003.

Mice are the most commonly used animal model for the study of inflammatory diseases. However, it has become increasingly apparent that results generated in mouse models reflect human disease poorly. Mice are highly resistant to most inflammatory challenges relative to humans. For example, mice are a million-fold more resistant to a common bacterial toxin, endotoxin, than humans. In addition, certain other vertebrate species, including some primates such as baboons, also evolved high natural resistance to inflammation. These mostly ignored observations seem essential in order to appropriately extrapolate results from studies in animal models to human disease. The failure of animal models to adequately mimic human disease is a major problem for biomedical research and for drug development. As a direct effect, there are costly errors and inefficiencies in the way that research is performed and drugs are developed. The Warren Lab is committed to understanding the reasons for the broad variation that exists across species in regards to inflammatory response.

The ultimate goal of SPIRIT is to take advantage of the innate resilience that some species such as mice have evolved to resist inflammation and to use this information to inspire novel treatment approaches for humans. Our earlier work suggests that one reason that resilient species such as mice can resist high degrees of inflammatory challenge may be that proteins in the plasma of mice re-program and down-regulate immune cells such as macrophages to resist secondary inflammatory toxicity. We are hopeful that this concept might be harnessed to transiently re-program human cells during acute inflammatory states to become resilient to pro-inflammatory stimuli. In essence, the SPIRIT program seeks to take advantage of the inherent resistance of mice and/or other resistant species to lead towards new treatment approaches for humans.

In addition to developing new treatments, SPIRIT may aid in the construction of better animal models of human inflammation. Since current mouse models do not mimic human disease very well because of the large differences in response to inflammation, knowledge on the re-programming of immune cells by mouse proteins to handle inflammation differently than humans should lead to development of more suitable mouse models. Understanding these differences would revolutionize biomedical research and drug and vaccine development. More information about this aspect of SPIRIT can be viewed in Dr. Warren’s TEDMED talk.

Specific research interests within SPIRIT include:

  1. Identification of serum proteins responsible for the marked resistance of mice (and other resistant species) to bacterial toxins
  2. Study and comparison of inflammatory gene responses to trauma and sepsis in different species.

We are exploring the inflammatory sensitivity and resistance of non-rodent species, including members of the primate order such as chimpanzees, baboons, and other primates that are more closely related to humans than mice. By studying primates that differ from humans in innate immune responses, we hope to elucidate mechanisms that might be more directly adapted for human approaches.

SPIRIT is by nature an interdisciplinary endeavor that requires cooperation from experts in several fields of study. Our research overlaps with the fields of genomics, systems biology, primatology, theoretical biology, and others. With this in mind, the Warren Lab is always excited to connect with investigators interested in potential collaboration. If you would be interested in further exploring this potential, feel free to contact Dr. Warren using the contact section of our site.

The Role of Heme in Inflammation

One early result of the SPIRIT approach is the Warren Lab’s work relating to the role of heme in inflammation. Researchers in our group (together with our collaborators at the Institut Pasteur in Paris) noted that mice respond much differently than humans to endotoxin challenge and that plasma proteins may be involved in their relative resistance. An effort to determine the responsible proteins led to the discovery of a heme-binding protein, hemopexin, which reduces the effects of heme and hemoglobin on macrophages. Although we now believe that hemopexin is not a dominant protein involved in causing the differential resistance of mice and humans to inflammation, we have learned that that extracellular heme may be important in amplifying tissue inflammation in the presence of additional inflammatory stimuli.

In patients with inflamed or necrotic tissues, it is common for microorganisms and degrading blood products to be present at the same time. In this situation, the integrity of red blood cells is lost and hemoglobin is released into the extracellular space. Hemoglobin is a metalloprotein that contains heme (a planar and hydrophobic porphyrin ring containing an iron atom, Fe2+, in the center of the ring). Heme serves as a reversible O2 binding site and redox center and its presence outside of red cell membranes leads to oxidizing injury. Extracellular hemoglobin is rapidly auto-oxidized, spontaneously releasing heme with direct tissue toxicity. We find that while hemoglobin and heme only minimally activate macrophages by themselves, both of these molecules markedly amplify the activation of macrophages when present at the same time as microbial and/or endogenous pro-inflammatory mediators. This finding may explain why the degrading red blood cell contents released after hemolysis or minor trauma or surgery only result in mild inflammation, whereas blood in tissues that is present at the same time as infection causes marked inflammation. The concept that tissue inflammation is driven or amplified by released hemoglobin and heme is a new paradigm.

Our laboratory has found that hemopexin strongly suppresses the amplified inflammatory response. Because this response is synergistic in nature, suppression of the heme component results in large decreases in pro-inflammatory cytokine production from cultured cells. We believe these findings raise the possibility that hemopexin might be helpful as a new treatment that could be used to decrease secondary inflammation in situations where there is rupture and degradation of red blood cells outside of the bloodstream in the presence of a second stimuli, such as microbes.

In order to facilitate translation to human trials it will be important to understand both the molecular mechanisms underlying the synergy and its suppression by hemopexin, as well as other heme-related parameters in relevant clinical settings. Current projects in the laboratory include:

  1. Efforts to further elucidate basic mechanisms underlying heme-induced inflammation
  2. Translational studies correlating heme parameters to outcome in multiple relevant clinical settings
  3. Determination of who might most benefit from hemopexin administration.

Research Positions

Project Manager

The Warren Lab is currently seeking a project manager to help coordinate the SPIRIT project. This is a large scale, multi-institution project focused on understanding and taking advantage of species differences in innate immunity to develop new strategies to treat inflammation. Please send inquiries to swarren1@partners.org.

Research Technologist

The Warren Lab is currently seeking a technologist to work on technical aspects of the SPIRIT project. Please send inquiries to swarren1@partners.org.


Original Articles

  1. Huan Yang, Haichao Wang, Yaakov A. Levine, Manoj K. Gunasekaran, Yongjun Wang, Meghan Addorisio, Shu Zhu, Wei Li, Jianhua Li, Dominique P.V. de Kleijn, Peder S. Olofsson, H. Shaw Warren, Mingzhu He, Yousef Al-Abed, Jesse Roth, Daniel J. Antoine, Sangeeta S. Chavan, Ulf Andersson, and Kevin J. Tracey. Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes. JCI Insight. 2016; 1(7):e85375. doi:10.1172/jci.insight.85375.
  2. Zeng MY, Cisalpino D, Varadarajan S, Hellman J, Warren HS, Cascalho M, Inohara N, Núñez G. Gut Microbiota-Induced Immunoglobulin G Controls Systemic Infection by Symbiotic Bacteria and Pathogens. Immunity. 2016; 44(3):647-58. PMID: 26944199
  3. Abers MS, Ghebremichael MS, Timmons AK; Warren HS; Poznansky MC; Vyas JM. Critical Reappraisal of Prolonged Neutropenia as a Risk Factor for Invasive Pulmonary Aspergillosis. Open Forum Infect Dis 2016 Feb 12; 3(1). doi: ofw036. doi: 10.1093/ofid/ofw036. eCollection 2016. PMID: 27006961
  4. Jones CN, Hoang AN, Martel JM, Dimisko L, Mikkola A, Inoue Y, Kuriyama N, Yamada M, Hamza B, Kaneki M, Warren HS, Brown DE, Irimia D. Microfluidic assay for precise measurements of mouse, rat, and human neutrophil chemotaxis in whole-blood droplets. J Leukoc Biol. 2016 Jan 27; pii: jlb.5TA0715-310RR. [Epub ahead of print]. PMID: 26819316
  5. Lin T, Liu J, Huang F, Van Engelen TS, Thundivalappil SR, Riley FE, Super M, Watters AL, Smith A, Brinkman N, Ingber DE, Warren HS. Purified and recombinant hemopexin: protease activity and effect on neutrophil chemotaxis. Mol Med. 2016 Jan 8. doi: 10.2119/molmed.2016.00006. [Epub ahead of print]. PMID: 26772775
  6. Elphinstone RE, Riley F, Lin T, Higgins S, Dhabangi A, Musoke C, Cserti-Gazdewich C, Regan RF, Warren HS, Kain KC. Dysregulation of the haem-haemopexin axis is associated with severe malaria in a case-control study of Ugandan children. Malar J. 2015 Dec 21;14(1):511. doi:10.1186/s12936-015-1028-1. PMID: 26691827
  7. Bhan I, Dobens D, Tamez H, Deferio JJ, Li YC, Warren HS, Ankers E, Wenger J, Tucker JK, Trottier C, Pathan F, Kalim S, Nigwekar SU, Thadhani R. Nutritional vitamin D supplementation in dialysis: a randomized trial. Clin J Am Soc Nephrol. 2015;10(4):611-9. PMID: 25770176
  8. Lin T, Maita D, Thundivalappil SR, Riley FE, Hambsch J, Van Marter LJ, Christou HA, Berra L, Fagan S, Christiani DC, Warren HS. Hemopexin in severe inflammation and infection: mouse models and human diseases. Crit Care. 2015 Apr 15; 19:166. doi: 10.1186/s13054-015-0885-x. PMID: 25888135
  9. Jones CN, Moore MM, Dimisko L, Alexander A, Ibrahim A, Hassell BA, Warren HS, Tompkins RG, Fagan SP, Irimia D. Spontaneus Neutrophil Migration Patterns during sepsis after major burns. PLoS One. 2014 Dec 9; 9(12):e114509. doi: 10.1371/journal.pone.0114509. eCollection 2014. PMID:25489947
  10. Leblanc P, Moise L, Luza C, Chantaralawan K, Lezeau L, Yuan J, Field M, Richer D, Boyle C, Martin WD, Fishman JB, Berg EA, Baker D, Zeigler B, Mais DE, Taylor W, Coleman R, Warren HS, Gelfand JA, De Groot AS, Brauns T, Poznansky MC. VaxCelerate II: Rapid Development of a Self-Assembling Vaccine for Lassa Fever. Hum Vaccin Immunother. 2014; 10(10):3022-38. PMID:25483693
  11. Malo MS, Moaven O, Muhammad N, Biswas B, Alam SN, Economopoulos KP, Gul SS, Hamarneh SR, Malo NS, Teshager A, Mohamed MM, Tao Q, Narisawa S, Millán JL, Hohmann EL, Warren HS, Robson SC, Hodin RA. Intestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotides. Am J Physiol Gastrointest Liver Physiol. 2014; 306(10):G826-38. PMID: 24722905
  12. Moss AK, Hamarneh SR, Mohamed MM, Ramasamy S, Yammine H, Patel P, Kaliannan K, Alam SN, Muhammad N, Moaven O, Teshager A, Malo NS, Narisawa S, Millán JL, Warren HS, Hohmann E, Malo MS, Hodin RA. Intestinal alkaline phosphatase inhibits the proinflammatory nucleotide uridine diphosphate. Am J Physiol Gastrointest Liver Physiol. 2013; 304(6):G597-604. doi: 10.1152/ajpgi.00455.2012. PMID: 23306083
  13. JunheeSeok, H. Shaw Warren, Alex G. Cuenca, Michael N. Mindrinos, Henry V. Baker, WeihongXu, Daniel R. Richards, Grace P. McDonald-Smith, Hong Gao, Laura Hennessy, Celeste C. Finnerty, M. Cecilia López, Shari Honari, Ernest E. Moore, Joseph P. Minei, Joseph Cuschieri, Paul E. Bankey, Jeffrey L. Johnson, Jason Sperry, Avery B. Nathens, Timothy R. Billiar, Michael A. West, Marc G. Jeschke, Matthew B. Klein, Richard L. Gamelli, Nicole S. Gibran, Bernard H. Brownstein, Carol Miller-Graziano, Steve E. Calvano, Philip H. Mason, John D. Storey, J. Perren Cobb, Laurence G. Rahme, Stephen F. Lowry, Ronald V. Maier, Lyle L. Moldawer, David N. Herndon, Ronald W. Davis, Wenzhong Xiao, Ronald G. Tompkins, and the Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Gene response in mouse models poorly mimics severe human inflammatory diseases. ProcNatlAcadSci U S A. 2013; 110(9):3507-12. PMID: 23401516
  14. Cuenca AG, Gentile LF, Lopez MC, Ungaro R, Liu H, Xiao W, Seok J, Mindrinos MN, Ang D, OzrazgatBaslanti T, Bihorac A, Efron PA, Cuschieri J, Warren HS, Tompkins RG, Maier RV, Baker HV, Moldawer LL; the Inflammation and Host Response to Injury Collaborative Research Program. Development of a Genomic Metric that can be Rapidly Used to Predict Clinical Outcome in Severely Injured Trauma Patients. Crit Care Med. 2013 May;41(5):1175-85. doi: 10.1097/CCM.0b013e318277131c. PMID: 23388514
  15. Kaliannan K, Hamarneh SR, Economopoulos KP, NasrinAlam S, Moaven O, Patel P, Malo NS, Ray M, Abtahi SM, Muhammad N, Raychowdhury A, Teshager A, Mohamed MM, Moss AK, Ahmed R, Hakimian S, Narisawa S, Millán JL, Hohmann E, Warren HS, Bhan AK, Malo MS, Hodin RA. Intestinal alkaline phosphatase prevents metabolic syndrome in mice. ProcNatlAcadSci U S A. 2013; 110(17):7003-8. PMID: 23569246
  16. Lin T, Sammy F, Yang H, Thundivalappil S, Hellman J, Tracey KJ, Warren HS. Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation. J Immunol. 2012; 189 (4):2017-22. PMID: 22772444
  17. Angel TE, Jacobs JM, Smith RP, Pasternack MS, Elias S, Gritsenko MA, Shukla A, Gilmore EC, McCarthy C, Camp DG 2nd, Smith RD, Warren HS. Cerebrospinal fluid proteome of patients with acute Lyme disease. J Proteome Res. 2012; 11(10):4814-22. PMID: 22900834
  18. Chan KE, Warren HS, Thadhani RI, Steele DJ, Hymes JL, Maddux FW, Hakim RM. Prevalence and Outcomes of Antimicrobial Treatment for Staphylococcus Aureus Bloodstream Infection in Outpatients with End-Stage Renal Disease. J Am Soc Nephrol. 2012; 23(9):1551-9. PMID: 22904350
  19. Cuschieri J, Johnson JL, Sperry J, West MA, Moore EE, Minei JP, Bankey PE, Nathens AB, Cuenca AG, Efron PA, Hennessy L, Xiao W, Mindrinos MN, McDonald-Smith GP, Mason PH, Billiar TR, Schoenfeld DA, Warren HS, Cobb JP, Moldawer LL, Davis RW, Maier RV, Tompkins RG. Benchmarking Outcomes in the Critically Injured Trauma Patient and the Effect of Implementing Standard Operating Procedures. Ann Surg. 2012; 255(5):993-9. PMID: 22470077
  20. Berra L, Coppadoro A, Yu B, Lei C, Spagnolli E, Steinbicker AU, Bloch KD, Lin T, Sammy FY, Warren HS, Fernandez BO, Feelisch M, Dzik WH, Stowell CP, Zapol WM. Transfusion of stored autologous blood does not alter reactive hyperemia index in healthy volunteers. Anesthesiology. 2012; 117(1):56-63. PMID: 22531338
  21. Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, Hayden DL, Hennessy L, Moore EE, Minei JP, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Brownstein BH, Mason PH, Baker HV, Finnerty CC, Jeschke MG, López MC, Klein MB, Gamelli RL, Gibran NS, Arnoldo B, Xu W, Zhang Y, Calvano SE, McDonald-Smith GP, Schoenfeld DA, Storey JD, Cobb JP, Warren HS, Moldawer LL, Herndon DN, Lowry SF, Maier RV, Davis RW, Tompkins RG; Inflammation and Host Response to Injury Large-Scale Collaborative Research Program. A genomic storm in critically injured humans. J Exp Med. 2011; 208(13):2581-90. PMID: 22110166
  22. Li Y, Si R, Feng Y, Chen HH, Zou L, Wang E, Zhang M, Warren HS, Sosnovik DE, Chao W.Myocardial ischemia activates an injurious innate immune signaling via cardiac heat shock protein 60 and Toll-like receptor 4. J. Biol Chem. 2011; 286(36):31308-19. PMID: 21775438
  23. Ebrahimi F, Malo MS, Alam SN, Moss AK, Yammine H, Ramasamy S, Biswas B, Chen KT, Muhammad N, Mostafa G, Warren HS, Hohmann EL, Hodin RA. Local Peritoneal Irrigation with Intestinal Alkaline Phosphatase Is Protective Against Peritonitis in Mice. J Gastrointest Surg. 2011; 15(5):860-9. PMID: 21360208
  24. Shin H-S , Xu F, Bagchi A, Herrup E, Prakash A, Valentine C, Kulkarni H, Wilhelmsen K, Warren HS, Hellman J. Bacterial lipoprotein Toll-like receptor 2 agonists broadly modulate endothelial function and coagulation pathways in vitro and in vivo. J Immunol. 2011; 186(2):1119-30. PMID: 21169547
  25. Chen KT, Malo MS, Beasley-Topliffe LK, Poelstra K, Millan JL, Mostafa G, Alam SN, Ramasamy S, Warren HS, Hohmann EL, Hodin RA. A Role for Intestinal Alkaline Phosphatase in the Maintenance of Local Gut Immunity. Dig Dis Sci. 2011; 56(4):1020-7. PMID: 20844955
  26. Ramasamy S, Nguyen DD Eston M, Alam SN, Moss AK, Ebrahimi F, Biswas B, Mostafa G, Chen KT, Kaliannan K, Yammine H, Narisawa S, Millán JL, Warren HS, Hohmann EL, Mizoguchi E, Reinecker H, Bhan AK, Snapper SB, Malo MS, Hodin RA. Intestinal Alkaline Phosphatase Has Beneficial Effects in Mouse Models of Chronic Colitis. Inflamm Bowel Dis. 2011; 17(2):532-42. PMID: 20645323
  27. Rajicic N, Cuschieri J, Finkelstein DM, Miller-Graziano CL, Hayden D, Moldawer LL, Moore E, O'Keefe G, Pelik K, Warren HS, Schoenfeld DA, and the Inflammation and the Host Response to Injury Large Scale Collaborative Research Program. Identification and interpretation of longitudinal gene expression changes in trauma. PLoS One. 2010; 5(12):e14380. PMID: 21187951
  28. Kotz KT, Xiao W, Miller-Graziano C, Qian WJ, Russom A, Warner EA, Moldawer LL, De A, Bankey PE, Petritis BO, Camp DG 2nd, Rosenbach AE, Goverman J, Fagan SP, Brownstein BH, Irimia D, Xu W, Wilhelmy J, Mindrinos MN, Smith RD, Davis RW, Tompkins RG, Toner M; the Inflammation and the Host Response to Injury Collaborative Research Program, Baker HV, Balis UG, Billiar TR, Calvano SE, Cobb JP, Cuschieri J, Finnerty CC, Gamelli RL, Gibran NS, Harbrecht BG, Hayden DL, Hennessy L, Herndon DN, Jeschke MG, Johnson JL, Klein MB, Lowry SF, Maier RV, Mason PH, McDonald-Smith GP, Minei JP, Moore EE, Nathens AB, O Keefe GE, Rahme LG, Remick DG, Schoenfeld DA, Shapiro MB, Sperry J, Storey JD, Tibshirani R, Warren HS, West MA, Wispelwey B, Wong WH. Clinical microfluidics for neutrophil genomics and proteomics. Nat Med. 2010; 16(9):1042-7. PMID: 20802500
  29. Zhou B, Xu W, Herndon D, Tompkins R, Davis R, Xiao W, Wong WH; Inflammation and Host Response to Injury Program, Toner M, Warren HS, Schoenfeld DA, Rahme L, McDonald-Smith GP, Hayden D, Mason P, Fagan S, Yu YM, Cobb JP, Remick DG, Mannick JA, Lederer JA, Gamelli RL, Silver GM, West MA, Shapiro MB, Smith R, Camp DG 2nd, Qian W, Storey J, Mindrinos M, Tibshirani R, Lowry S, Calvano S, Chaudry I, West MA, Cohen M, Moore EE, Johnson J, Moldawer LL, Baker HV, Efron PA, Balis UG, Billiar TR, Ochoa JB, Sperry JL, Miller-Graziano CL, De AK, Bankey PE, Finnerty CC, Jeschke MG, Minei JP, Arnoldo BD, Hunt JL, Horton J, Cobb JP, Brownstein B, Freeman B, Maier RV, Nathens AB, Cuschieri J, Gibran N, Klein M, O'Keefe G. Analysis of factorial time-course microarrays with application to a clinical study of burn injury. Proc Natl Acad Sci U S A. 2010; 107(22):9923-8. PMID: 20479259
  30. Malo MS, Alam SN, Mostafa G, Zeller SJ, Johnson PV, Mohammad N, Chen KT, Moss AK, Ramasamy S, Faruqui A, Hodin S, Malo PS, Ebrahimi F, Biswas B, Narisawa S, Millán JL, Warren HS, Kaplan JB, Kitts CL, Hohmann EL, Hodin RA. Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut. 2010; 59(11):1476-84. PMID: 20947883
  31. Chen KT, Malo MS, Moss AK, Zeller S, Johnson P, Ebrahimi F, Mostafa G, Alam S, Ramasamy S, Warren HS, Hohmann E, Hodin RA. Identification of Specific targets for the gut mucosal defense factor intestinal alkaline phosphatase, Am J Physiol Gastrointest Liver Physiol. 2010; 299(2):G467-75. PMID: 20489044
  32. Lin T, Kwak Y, Sammy F, He P, Thundivalappil S, Sun G, Chao W, Warren HS. Synergistic inflammation is induced by blood degradation products with microbial Toll-like receptor agonists and is blocked by hemopexin, J Infect Dis. 2010;202(4):624-32 PMID: 20617898
  33. Warren HS, Fitting C, Hoff E, Beasley-Topliffe L, Tesini B, Liang X, Adib-Conquy M, Valentine C, Hellman J, Hayden D, Cavaillon JM. Resilience to bacterial infection: difference between species could be due to proteins in serum. J Infect Dis. 2010; 201(2):223-32. PMID: 20001600
  34. Cobb JP, Moore EE, Hayden DL, Minei JP, Cuschieri J, Yang J, Li Q, Lin N, Brownstein BH, Hennessy L, Mason PH, Schierding WS, Dixon DJ, Tompkins RG, Warren HS, Schoenfeld DA, Maier RV. Validation of the Riboleukogram to Detect Ventilator-Associated Pneumonia after Severe Injury. Ann Surg. 2009; 250(4):531-9. PMID: 19730236
  35. Warren HS, Elson CM, Hayden DL, Schoenfeld DA, Cobb JP, Maier RV, Moldawer LL, Moore EE, Harbrecht BG, Pelak K, Cuschieri J, Herndon DN, Jeschke MG, Finnerty CC, Brownstein BH, Hennessy L, Mason PH, Tompkins RG. Inflammation and Host Response to Injury Large Scale Collaborative Research Program. Genomic Score Prognostic of Outcome in Trauma Patients. Mol Med. 2009; 15(7-8):220-7. PMID: 19593405
  36. Liang X, Lin T, Sun G, Beasley-Topliffe, L, Cavaillon J-M, Warren HS. Hemopexin downregulates LPS-induced pro-inflammatory cytokines from macrophages. J Leukoc Biol. 2009; 86(2):229-35. PMID: 19395472
  37. Goldberg RF, Austen WG, Zhang X, Munene G, Mostafa G, Biswas S, McCormack, M, Eberlin, K, Nguyen JT, Tatlidede HS, Warren HS, Narisawa S, Malo MS, Millán JL and Hodin RA. Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci U S A. 2008; 105(9):3551-6. PMID: 18292227
  38. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, Valentine C, Hellman J. MyD88 dependent and MyD88 independent pathways in synergy, priming, and tolerance between toll-like receptors agonists. J Immunol. 2007; 178(2):1164-71. PMID: 17202381
  39. Valentine CH, Hellman J, Beasley-Topliffe L, Bagchi A, and Warren HS. Passive immunization to outer membrane proteins MLP and PAL does not protect mice from sepsis. Molecular Medicine. 2006; 12(9-10):252-8. PMID: 17225874
  40. Cobb JP, Mindrinos MN, Miller-Graziano C, Calvano SE, Baker HB, Xiao W, Laudanski K, Brownstein BH, Elson CM, Hayden DL, Herndon DL, Lowry SF, Maier RV, Schoenfeld DA, Moldawer L, Davis RW, Tompkins RG, Inflammation and Host Response to Injury Large-Scale Collaborative Research Program, Baker HB,. Bankey P, Billiar T, Brownstein, BH, Calvano SE Camp D, Chaudry I, Cobb, JP, Davis RW, Elson, CM, Bradley F, Gamelli R, Gibran N, Harbrecht B, Hayden, DL, Haegy W, Deimbach D, Herndon DN, Horton, J, Hunt J, Laudanski K, Lederer J, Lowry SF Maier RV, Mannick J, McKinley B, Miller-Graziano C, Mindrinos MN, Minei J, Moldawer L, Moore E, Moore F, Munford R, Nathens A, O'Keefe K, Purdue, G, Rahme L, Remick D, Sailors M, Schoenfeld D, Shapiro M, Siler G, Smith R, Stephanopoulos G, Stormo G, Tompkins, RG, Toner M, Warren HS, West M, Wolfe S, Xiao W. and Young V. Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A. 2005; 102(13):4801-6. PMID: 15781863
  41. Liang, MD, Bagchi, A, Warren HS, Tehan MM, Trigilio JA, Beasley-Topliffe L, Tesini B, Lazzaroni J-C, Fenton M, Hellman J. Bacterial peptidoglycan-associated lipoprotein: a potent toll-like receptor 2 agonist that is shed into serum and is synergistic with LPS. J. Infect Disease. 2005; 191:939-948. PMID: 15717270
  42. Copeland S, Warren HS, Lowry SF, Cavlano SE. Remick D and the Inflammation and Host Response to Injury Large Scale Collaborative Research Program. The acute inflammatory response to endotoxin in mice and humans. Clinical and Diagnostic Laboratory Immunology 2005; 12: 60-67. PMID: 15642986
  43. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susaria SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ. Reversing established sepsis with antagonists of endogenous HMGB1. Proc Natl Acad Sci U S A. 2004; 101(1): 296-301. PMID: 14695889
  44. Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X, Harris HE, Czura CJ, Wang H, Ulloa L, Wang H, Warren HS, Moldawer LL, Fink MP, Andersson U, Tracey KJ, Yang H. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med. 2003; 9(1-2):37-45. PMID: 12765338
  45. Cross AS, Opal SM, Palardy JE, Drabick JJ, Warren HS, Huber C, Cook P, Bhattaacharajee AK. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/ group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine. 2003; 21(31): 4576-87. PMID: 14575770
  46. Warren HS, Matyal R, Allaire JE, Yarmush D, Loiselle P, Hellman J, Paton BG, Fink MP. Protective efficacy of CAP18106-138-IgG in sepsis. J. Infect. Dis. 2003; 188:1382-1393. PMID: 14593598
  47. Hellman J, Tehan, MM, Warren HS. Murein lipoprotein (MLP), peptidoglycan-associated lipoprotein (PAL), and outer membrane protein A (OmpA) are present in purified rough and smooth LPS. J Infect Dis. 2003; 188(2):286-9. PMID: 12854085
  48. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. New Eng. J. Med. 2002; 347:1027-1030. PMID: 12324562
  49. Hellman J, Roberts JD, Tehan MM, Allaire J, Warren HS. Bacterial peptidoglycan-associated lipoprotein is released into the bloodstream in Gram-negative sepsis and causes inflammation and death in mice. J Biol Chem. 2002; 277(16):14274-80. PMID: 11830585
  50. Hellman J and Warren HS. Outer membrane protein A (OmpA), Peptidoglycan associated lipoprotein (PAL), and murein lipoprotein (MLP) are released in experimental gram-negative sepsis. J Endotoxin Res. 2001; 7(1):69-72. PMID: 11521086
  51. Cross AS, Opal SM, Warren HS, Palardy JE, Buffum K, Parejo NA, Bhattacharjee AK. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide–group B meningococcal outer membrane protein complex vaccine protects immunocompromised animals from experimental Klebsiella and Pseudomonas sepsis. J. Infect. Dis. 2001;183: 1079-1086. PMID: 11237833
  52. Chapman RG, Ostuni E, Liang MN, Meluleni G, Kim E, Yan L, Pier G, Warren HS, Whitesides GM. Polymeric thin films that resist the adsorption of proteins and the adhesion of bacteria. Langmuir. 2001; 17:1225-1233.
  53. Hellman J, Loiselle PM, Tehan MM, Allaire JE, Boyle LA, Kurnick JT, Andrews DM, Warren HS. Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum. Infect. Immun. 2000;68:2566-2572. PMID: 10768945
  54. Hellman J, Loiselle PM, Zanzot EM, Allaire JE, Tehan MM, Boyle LA, Kurnick JT, Warren HS. Release of Gram-negative outer membrane proteins into human serum and septic rat blood and their interactions with immunoglobulin in antiserum to heat-killed Escherichia coli J5. J. Infect. Dis. 2000; 181:1034-1043. PMID: 10720528
  55. Ge Y, Ezzell RM, Warren HS. Localization of endotoxin in the rat intestinal epithelium. J. of Infect. Dis. 2000; 182; 873-881. PMID: 10950783
  56. Busch, NA, Zanzot EM, Loiselle PM, Carter EA, Yarmush ML, Warren HS. A model of infected burn wounds using E. coli O18K1 for the study of Gram-negative bacteremia and sepsis. Infect. Immun. 2000; 68; 3349-3351. PMID: 10816484
  57. Rao J, Yan L, Lahiri J, Whitesides GM, Weis RM, Warren HS. Binding of a dimeric derivative of vancomycin to L-Lys-D-Ala-D-lactate in solution and at a surface: insights into its enhanced activity against vancomycin resistant bacteria. Chem Biol. 1999; 6:353-9. PMID: 10375541
  58. Hellman J, Warren HS. Antibodies against bacterial membrane proteins. J. of Endotoxin Research. 1999; 4:213-215.
  59. Ge Y, Ezzell RM, Clark BD, Loiselle PM, Amato SF, Warren HS. Relationship of tissue and cellular IL-1 and LPS after endotoxemia and bacteremia. J. Infect. Dis. 1997; 176:1313-1321. PMID: 9359733
  60. Hellman J, Zanzot EM, Loiselle PM, Amato SF, Black KM, Ge Y, Kurnick JT, Warren HS. Antiserum against escherichia coli J5 contains antibodies reactive with outer membrane protein of heterologous gram-negative bacteria. J. Infect. Dis. 1997; 176:1260-1268. PMID: 9359727
  61. Ogata M., Fletcher MF, Kloczewiak M, Loiselle PM, Zanzot EM, Vermeulen MW, Warren HS. The effect of anticoagulants on LPS binding and neutralization by the peptide-immunoglobulin conjugate, CAP18106-138-IgG, in whole blood. Infect. Immun. 1997; 65:2160-2167. PMID: 9169746
  62. Fletcher MF, Kloczewiak MA, Loiselle PM, Ogata M, Vermeulen MW, Zanzot EM, Warren HS. A novel peptide-IgG conjugate, CAP18106-138-IgG, that binds and neutralizes endotoxin and kills gram-negative bacteria. J. Infect. Dis. 1997; 175:621-632. PMID: 9041334
  63. Fletcher MA, Kloczewiak M, Loiselle PM, Amato SF, Black KM, Warren HS. TALF peptide-immunoglobulin G conjugates that bind lipopolysaccharide. J. Endotoxin Research. 1996; 3: 49-55.
  64. Kloczewiak M, Black KM, Loiselle P, Cavaillon J-M, Wainwright N, Warren HS. Synthetic peptides that mimic the binding site of horseshoe crab antilipopolysaccharide factor. J Infect Dis. 1994; 170:1490-1497. PMID: 7995989
  65. Kersten CM, McCluskey RT, Warren HS, Kurnick JT. Responses of human T Cell to dominant discrete protein antigens of Escherichia coli and Pseudomonas aeruginosa. Scand J Immunol. 1994; 40:151-157. PMID: 751935
  66. Larrick JW, Hirata M, Zheng H, Zhong J, Bolin D, Cavaillon JM, Warren HS, Wright SC. A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J Immunol. 1994; 152:231-240. PMID: 8254193
  67. Ge Y, Ezzell RM, Tompkins RG, Warren HS. Cellular distribution of endotoxin after injection of chemically purified lipopolysaccharide differs from that after injection of live bacteria. J Infect Dis. 1994; 169:95-104. PMID: 8277203
  68. Wilz SW, Kurnick JT, Pandolfi F, Rubin RH, Warren HS, Goldstein R, Kersten CM, McCluskey RT. T Lymphocyte responses to antigens of gram-negative bacteria in pyelonephritis. Clin Immunol Immunopathol. 1993; 69:36-42. PMID: 8403542
  69. Warren HS, Amato SF, Fitting C, Black K, Loisette P, Pasternack MS, Cavaillon J-M. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J. Exp. Med. 1993; 177:89-97. PMID: 841821
  70. Chen TY, Warren HS, Greene BA, Black K, Frostell CG, Robinson DR, Zapol WM. Protective effects of anti-O polysaccharide and anti-lipid A monoclonal antibodies on the ovine pulmonary circulation. J. App. Physiol. 1993; 74:423-427. PMID: 8444723
  71. Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. N. Eng J Med. 1992; 326:1153-1157. PMID: 1552919
  72. Warren HS, Glennon ML, Wainwright N, Amato SF, Black KM, Kirsch SJ, Riveau GR, Whyte RI, Zapol WM, Novitsky TJ. Binding and neutralization of endotoxin by limulus antilipopolysaccharide factor. Infect Immun. 1992; 60:2506-2513. PMID: 1587618
  73. Warren HS, Glennon M, de Deckker FA, Tello D. Role of Normal Serum in the binding of Lipopolysaccharide to IgG fractions from rabbit antisera to Escherichia coli J5 and other gram-negative bacteria. J. Infect. Dis. 1991; 163:1256-1266. PMID: 1709961
  74. Cavaillon JM, Fitting C, Haeffner-Cavaillon N, Kirsch SJ, Warren HS. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect. Immun. 1990; 58:2325-2382. PMID: 2114366
  75. Whyte RI, Warren HS, Greene E, Glennon ML, Robinson DR, Zapol WM. Tolerance to low-dose endotoxin in the awake sheep. J. Appl. Physiol. 1989; 66(6):2546-2552. PMID: 2663818
  76. Warren HS, Riveau GR, de Deckker FA, Chedid LA. Control of endotoxin activity and Interleukin-1 production by regulation of lipopolysaccharide-lipoprotein binding by a macrophage factor. Infect. Immun. 1988; 56:204-212. PMID: 3275583
  77. Riveau GR, Novitsky TJ, Roslansky PF, Dinarello CA, Warren HS. Role of Interleukin-1 in augmenting serum neutralization of bacterial lipopolysaccharide. J.Clin. Micro. 1987; 25:889-892. PMID: 3495548
  78. Warren HS, Novitsky T, Bucklin A, Kania S, Siber GR. Endotoxin neutralization by rabbit antisera to Escherichia coli J5 and other gram-negative organisms. Infect. Immun. 1987; 55:1668-1673. PMID: 3298063
  79. Warren HS, Knights C, Siber GR. Neutralization and lipoprotein binding of lipopolysaccharides in tolerant rabbit serum. J. Infect. Dis. 1986; 154:784-791. PMID: 3095436
  80. Siber GR, Kania S, Warren HS. Cross reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria. J. Infect. Dis. 1985; 152:954-964. PMID: 2413146
  81. Novitsky TJ, Roslansky PF, Siber GR, Warren HS. A turbidometric method for quantifying serum inhibition of Limulus Ameobocyte lysate response. J. Clin. Micro. 1985; 20:211-216. PMID: 3972988
  82. Warren HS, Novitsky TJ, Ketchum PA, Roslansky PF, Kania SA, Siber GR. Neutralization of bacterial lipopolysaccharides by human plasma. J. Clin. Micro. 1985; 22:590-595. PMID: 3908471
  83. Warren HS, Kania S, Siber GR. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrobial Agents and Chemotherapy. 1985; 28:107-112. PMID: 2412488
  84. Warren HS, Schreiber JR, Epstein MF. Necrotizing enterocolitis and homolysis associated with Clostridium perfringens. Amer. J. Dis. Child. 1984; 138:686. PMID: 6328971

Chapters, Reviews, Editorials

  1. Warren HS, Tompkins RG, Moldawer LL, Seok J, Xu W, Mindrinos MN, Maier RV, Xiao W, Davis RW. Mice are not men. Proc Natl Acad Sci USA. 2015; 112(4):E345. PMID: 25540422
  2. Fink MP, Warren HS. Strategies to improve drug development for sepsis. Nat Rev Drug Discov. 2014; 13(10):741-58. PMID: 25190187
  3. Warren S. You are not a mouse. So why test drugs on them? Wired magazine, Ideas Bank, October 6, 2014.
  4. Tompkins RG, Warren HS, Mindrinos MN, Xiao W, Davis RW. Reply to Osterburg et al.: To study human inflammatory diseases in humans. Proc Natl Acad Sci USA. 2013; 110(36):E3371. PMID: 24137798
  5. Warren HS, Tompkins RG, Mindrinos MN, Xiao W, Davis RW. Reply to Cauwels et al.: Of men, not mice, and inflammation.  Proc Natl Acad Sci USA. 2013; 110(34):E3151. PMID: 24137663
  6. Catlin EA, Warren HS, Shailam R, Lahoud-Rahme M, Lew M. Madelyn. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. A Premature Newborn Boy with Respiratory Distress," N Engl J Med. 2012; 366(25):2409-19. PMID: 22716980
  7. Warren HS. Control issues in sepsis: what modulates apoptosis. J Leukoc Biol. 2011; 89(3):325-6. PMID: 21357246
  8. Warren HS. The immunopathophysiological state of sepsis. 39th Critical Care Conference Review, Society of Critical Care Medicine. 2010.
  9. Warren HS. Mouse models to study sepsis syndrome in humans. J Leukoc Biol. 2009; 86(2):199-201.
  10. Warren HS. PPARγ agonists, control of bacterial overgrowth, and inflammation. Critical Care Medicine. 2009; 37:773
  11. Warren HS. Toll-like receptors. Critical Care Medicine. 2005; 33: S457-9
  12. Tracey KJ, Warren HS. Human genetics. An inflammatory issue. Nature. 2004; 429(6987):35-7.
  13. Warren HS, Gonzalez RG, Tian D. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-2003. A 12-year-old girl with fever and coma. N Engl J Med. 2003; 349(24): 2341-9.
  14. Warren HS. Sepsis Syndrome. Infectious Disease Medicine Book of Medical Knowledge Self-Assessment Program 13 (MKSAP 13) – American College of Physicians-American Society of Internal Medicine. 2003.
  15. Warren HS. Understanding sepsis: new findings, new theories. Medscape Infectious Diseases. 1999.
  16. Hellman J, Warren HS. Anti-endotoxin strategies. Infectious Disease Clinics of North America, 1999; 13: 371-386.
  17. Warren HS, Leclerc C. Adjuvants. In: Roitt IM and Delves PJ, eds. Encyclopedia of Immunology, 2nd edition, Academic Press, London. 1998.
  18. Warren HS. Strategies for treating sepsis. New Eng. J. Med. 1997; 336: 952-953. Editorial.
  19. Bhattacharjee AK, Cross AS, Opal SM, Warren HS, Sadoff JC. New trends in Escherichia coli O111:B4 J5 mutant [Rc chemotype] vaccine development for use in Gram-negative bacillary sepsis. In Morrison DC and Ryan JL, eds. Novel therapeutic strategies in the treatment of sepsis. Marcel Dekker Inc. New York. 1996
  20. Lynfield R, Warren HS. Antimicrobial treatment of sepsis in the pediatric intensive care unit. In Todres D and Fugate J, eds. Critical Care of Infants and Children, Little, Brown and Co, Boston. 1996.
  21. Warren HS, Bailey EM. A 57 year old man with chronic active hepatitis, a rapidly progressive bullous eruption, and shock. Case records of the Massachusetts General Hospital. N Engl J Med. 1994; 331:1362-1368.
  22. Warren HS. Adjuvants. In: Roitt IM and Delves PJ, eds. Encyclopedia of Immunology. Philadelphia: W.B. Saunders Co. 1992.
  23. Warren HS, Burke JF. Infection of burn wounds:  evaluation and management. In: Swartz MN and Remmington JS, ed. Current Clinical Topics in Infectious Disease, 11th ed. Blackwell Scientific Press. 1991.
  24. Warren HS. Humoral aspects of endotoxin neutralization. In: Lemaire F, Zapol WM, eds. Lung Biology in Health and Disease, Acute Respiratory Failure. 2nd ed. New York: Marcel Dekker, Inc. 1990.
  25. Warren HS, Chedid LA. Future prospects for vaccine adjuvants. CRC Critical Reviews in Immunology. 1988; 8:83-101.
  26. Warren HS, Chedid LA. Strategies for the treatment of endotoxemia; significance of the acute phase response. Rev. Infect. Dis. 1987; 9:S630-S638.
  27. Warren HS, Novitsky T, Rolansky P, Martin P, Siber GR. Endotoxin neutralizing capacity of sera from different patient populations assessed by the Limulus lysate test. In: Watson S, ed. Endotoxins and their detection with the limulus amoebocyte lysate test. New York: Alan Liss Inc. 1986.
  28. Warren HS, Vogel FR, Chedid LA. Current status of immunological adjuvants. Ann. Rev. Immunol. 1986; 4:369-388.


Warren Lab
Massachusetts General Hospital - East
149 13th Street
Charlestown, MA 02129

Phone: 617-726-5774

Directions to the Warren Lab

The Warren Lab is located in the Charlestown Navy Yard, in the main research building of Mass General. The address is 149 13th Street, Charlestown, MA 02129. Our building is sometimes referred to as MGH East, and is on Boston Harbor, very close to the USS Constitution. We are a 15 minute shuttle bus ride away from the main Mass General campus in Boston.

Please note: Once you arrive at the building, if you do not have a Mass General security badge, you must check in at Security Desk for a temporary pass and an escort.


Parking is available at the parking garage adjacent to 149 13th building.

Public Transport Directions

Via the MBTA Green or Orange Line and the Partners HealthCare Shuttle

  • Take the MBTA Green or Orange Line to North Station
  • The free Partners HealthCare Shuttle Bus picks up on Causeway Street, just outside the North Station T station, across from the TD Garden. The shuttle will bring you directly to 149 13th Street. The shuttle departs every 15 minutes during working hours, less often on weekends and holidays. The shuttle is free and you do not need identification or validation. View the Partners HealthCare Shuttle schedule.

Via the MBTA Red Line and the Partners HealthCare Shuttle

  • Take the MBTA Red Line to Charles/MGH Station
  • Take the free Partners HealthCare Shuttle Bus #2 from the stop on Blossom Street, behind Massachusetts General Hospital or outside of 50 Staniford Street. The shuttle departs every 15 minutes during working hours, less often on weekends and holidays. The shuttle is free and you do not need identification or validation. View the Partners HealthCare Shuttle schedule.

Driving Directions

From Points North

  • From I-93 S, take Exit 28 toward Sullivan Square/Charlestown
  • Take the ramp to Sullivan Square/Charlestown
  • Merge onto Maffa Way and continue onto Cambridge Street
  • Turn right toward New Rutherford Avenue
  • Turn left at Chelsea Street
  • After the fourth traffic light, turn right at 13th Street

From Points South

  • From I-93 N/MA-3 N toward Boston
  • Take Exit 23 toward Government Center
  • Take the North End ramp toward Charlestown
  • Turn left onto Cross Street
  • Turn slight right onto Joe Tecce Way/North Washington Street
  • Continue on to the Charlestown Bridge/N Washington Street
  • Across the bridge, turn right at Chelsea Street
  • After the fourth traffic light, turn right at 13th Street

From Points West via Storrow Drive

  • At the end of Storrow Drive/Massachusetts 3A, just before the entrance ramp for 93N, take a sharp right on Martha Road
  • Turn left at Causeway Street
  • Turn left at Charlestown Bridge/N Washington Street
  • Across the bridge, turn right at Chelsea Street
  • After the fourth traffic light, turn right at 13th Street

From Logan Airport

  • Take I-90 W
  • Take Exit 24 to merge onto I-93 N
  • Take the exit on the left
  • Continue straight onto N Washington St 0.2 mi
  • Turn right at Causeway Street
  • Turn left at Charlestown Bridge/N Washington Street
  • Across the bridge, turn right at Chelsea Street
  • After the fourth traffic light, turn right at 13th Street

Back to Top